DRAPER, Utah, Oct. 25, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to report that the Company has shipped the first of two orders for its patented AES™ (Assimilation Enhancing System) enzyme blend to Watakura Corp. in Yokohama, Japan. "Mr. Mori Shinichiro, CEO of Watakura Corp., and I have a business relationship of over 16 years. He is an expert in the ingredient supply industry and consults with some of Japan's largest dietary supplement companies," explained Nutranomics' CEO Dr. Tracy K. Gibbs. "Getting orders from his company will give us a foothold in a country whose supplement-buying power is second only to the USA." This multiple shipment purchase order for AES is part of an ongoing Asian market and new product expansion currently being undertaken by the Company. About NutranomicsNutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia. For further information regarding Nutranomics, Inc., please contact our investor relations representatives at email@example.com or call toll-free (888) 616-3999. Notice Regarding Forward-Looking StatementsThis news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include the Company's plan to execute and accelerate its global sales and marketing plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. SOURCE Nutranomics, Inc.